MorphoSys AG
FRANKFURT : MOR

April 18, 2012 01:55 ET

MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - Apr 18, 2012) - MorphoSys AG / MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday, May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a member of MorphoSys AG's Supervisory Board since 1998, while Dr. Colpan joined in 2004.

"We are delighted to be able to present two highly qualified candidates for MorphoSys's Supervisory Board," commented Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG. "Karin Eastham and Marc Cluzel both have outstanding track records in our industry and have contributed to the successful performance of several companies over the course of their careers."

Karin Eastham is an experienced financial executive who currently serves as director on the Corporate Boards of Illumina, Inc., Amylin, Inc., Trius Therapeutics, Inc. and Geron Corporation. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer and as a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc. and Cytel Corporation. She also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. and a M.B.A. from Indiana University and is a Certified Public Accountant.

Dr. Marc Cluzel, an established innovator and leader in the pharmaceutical industry, has more than 20 years of extensive knowledge and experience in Research & Development and product registration in the USA, Europe and Japan. Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice President of Product Development at HÙYÀ Bioscience International, LLC. Dr. Cluzel served as global head of R&D for Sanofi from 2007 to 2011, as Executive Vice President of Research & Development for Sanofi (Formerly Sanofi-Aventis SA) and before 2009 as its Senior Vice President of Science and Medical Affairs. He was also since 2002 chairman and CEO of Sanofi-Synthelabo R&D France then Sanofi-Aventis R&D France. His career began in hospital medical care and gradually transitioned to research at Johns Hopkins University, Baltimore and Guy's Hospital, London. Dr. Cluzel holds both an MD and a PhD from the University of Montpellier, France.

The full agenda for the Annual General Meeting is available on the Company's website under www.morphosys.com/agm.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and arYla® are registered trademarks of MorphoSys. Ylanthia® and 100 billion high potentials™ are trademarks of MorphoSys AG.


Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release: http://hugin.info/130295/R/1603237/506731.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1603237]

Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact